Metabolism-Based Blood Test to Detect Multiple Cancer Types Prior to Symptoms
|
By LabMedica International staff writers Posted on 22 Jun 2022 |
|
A pioneering metabolism-based liquid biopsy could detect any-type cancer in adults who show no symptoms or have any recent history of cancer, thereby preventing cancer mortality through early detection.
Elypta (Stockholm, Sweden), which aims to commercialize the first metabolism-based liquid biopsy for early detection of any cancer, will develop and validate blood and urine tests for Multi-Cancer Early Detection (MCED) in adults with no symptoms of cancer and for detection of recurrence in kidney cancer patients. The tests are based on the exhaustive profiling of human glycosaminoglycans - also known as the GAGome - as biomarkers of cancer metabolism, an approach pioneered by Elypta.
Metabolic reprogramming is a hallmark of cancer. Cancer cells need to rewire the way they procure energy and nutrients to support abnormal proliferation and growth. Yet, metabolism is an under-investigated layer of information to identify biomarkers for cancer. By overlaying genome-wide omics data onto the largest reconstruction of the human metabolic network, Elypta identified the profile of the GAGome as the most deregulated panel of metabolites in cancer.
Recent evidence suggests that metabolic reprogramming of GAGomes is a ubiquitous process in cancers. In a clinical study with over 1500 samples across 14 cancer types, a multi-cancer GAGome signature was detected in the plasma and urine that was significantly elevated already in stage I in every cancer type tested. Preclinical evidence in mice supports a causal link between cancer initiation and changes in the GAGome providing mechanistic insight on its value for early detection.
“Our MCED test has the potential to greatly increase the share of cancers detected at the earliest stages when treatment could mean a cure besides being less costly,” said Francesco Gatto, CSO & Founder of Elypta. “Detecting stage I cancer is the key challenge here, and whereas other MCED tests based on cell free DNA struggle to find cancer at this early stage, metabolism-based biomarkers could really make a difference.”
Related Links:
Elypta
Latest Molecular Diagnostics News
- Genetic Test Could Predict Poor Outcomes in Lung Transplant Patients
- Breakthrough Blood Test Enables Early Pancreatic Cancer Detection
- Genomic Testing in NICU Reduces Missed Diagnoses
- New Genetic Test Improves Diabetes Prediction and Classification
- New Blood Test for Leukemia Risk Detection Could Replace Bone Marrow Sampling
- Blood Test Detects Preeclampsia Risk Months Before Symptoms Appear
- mNGS CSF Test Outperforms Traditional Microbiological Testing for Infectious Diseases
- Point-Of-Care Test to Transform Early-Stage Cervical Cancer Diagnosis
- PET/ctDNA-Guided Approach Helps Determine Lymphoma Treatment
- Next-Generation 'Agnostic Diagnostics' to Detect Respiratory Viruses at POC
- First-Ever Test of Cure for Chagas Disease Determines Treatment Effectiveness
- Capsule Sponge Test Could Replace Endoscopies for Monitoring Esophageal Cancer Risk
- Nasal Swab Test Offers Simpler and Less Costly Virus Screening in High-Risk Settings
- DNA Test Accurately Predicts Resistance to Common Chemotherapy Treatments
- Umbilical Cord Blood Test Can Detect Early Sepsis in Preterm Infants
- Simple Blood Test Predicts Cognitive Decline in Alzheimer's Patients
Channels
Clinical Chemistry
view channel
New Reference Measurement Procedure Standardizes Nucleic Acid Amplification Test Results
Nucleic acid amplification tests (NAATs) play a key role in diagnosing a wide range of infectious diseases. These tests are generally known for their high sensitivity and specificity, and they can be developed... Read more
Pen-Like Tool Quickly and Non-Invasively Detects Opioids from Skin
Opioid drugs such as fentanyl, morphine, and oxycodone are the primary substances associated with overdose cases in the United States. Standard drug screening procedures typically involve collecting blood,... Read more
Hematology
view channel
Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results
Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read more
Immunology
view channel
Blood Test Detects Organ Rejection in Heart Transplant Patients
Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Liquid Biopsy Approach to Transform Diagnosis, Monitoring and Treatment of Lung Cancer
Lung cancer continues to be a major contributor to cancer-related deaths globally, with its biological complexity and diverse regulatory processes making diagnosis and treatment particularly difficult.... Read more
Computational Tool Exposes Hidden Cancer DNA Changes Influencing Treatment Resistance
Structural changes in tumor DNA are among the most damaging genetic alterations in cancer, yet they often go undetected, particularly when tissue samples are degraded or of low quality. These hidden genomic... Read more
Microbiology
view channel
Credit Card-Sized Test Boosts TB Detection in HIV Hotspots
Current tuberculosis (TB) tests face major limitations when it comes to accurately diagnosing the infection in individuals living with HIV. HIV, a frequent co-infection with TB, complicates detection by... Read more
Fecal Metabolite Profiling Predicts Mortality in Critically Ill Patients
Critically ill patients in medical intensive care units (MICUs) often suffer from conditions such as acute respiratory distress syndrome (ARDS) or sepsis, which are linked to reduced diversity of gut microbiota... Read more
Portable Molecular POC System Rules Out UTIs in Just 35 Minutes
Urinary tract infections (UTIs) represent a massive burden on patients and healthcare systems. There are over 400 million UTI cases globally each year, of which around 90% are in women. Fast and accurate... Read more
POC Lateral Flow Test Detects Deadly Fungal Infection Faster Than Existing Techniques
Diagnosing mucormycosis—an aggressive and often deadly fungal infection—remains a major challenge due to the disease’s rapid progression and the lack of fast, accurate diagnostic tools. The problem became... Read morePathology
view channel
Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response
Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Clinical AI Solution for Automatic Breast Cancer Grading Improves Diagnostic Accuracy
Labs that use traditional image analysis methods often suffer from bottlenecks and delays. By digitizing their pathology practices, labs can streamline their work, allowing them to take on larger caseloads... Read more
Saliva-Based Testing to Enable Early Detection of Cancer, Heart Disease or Parkinson’s
Saliva is one of the most accessible biological fluids, yet it remains underutilized in clinical practice. While saliva samples are used to perform genetic tests to determine, for example, paternity, the... Read more
Technology
view channel
New POC Biosensing Technology Improves Detection of Molecular Biomarkers
Traditional diagnostic procedures in medicine typically involve sending a patient’s blood or tissue samples to clinical laboratories, where trained scientists perform testing and data interpretation.... Read more
Enhanced Lab Data Management and AI Critical to Labs of the Future, Finds Survey
Data plays a key role in the transformation of today’s digital laboratories, acting both as a key challenge and a catalyst for innovation, as revealed by a survey of over 150 scientists.... Read more
Industry
view channel
AMP Releases Best Practice Recommendations to Guide Clinical Laboratories Offering HRD Testing
Homologous recombination deficiency (HRD) testing identifies tumors that are unable to effectively repair DNA damage through the homologous recombination repair pathway. This deficiency is often linked... Read more
